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products in Europe as compared to the US. CONCLUSION:
While European regulatory bodies have long-embraced QoL/
PROs (along with efﬁcacy and safety) as key endpoints for
approval, the FDA is starting to acknowledge pharmacoeco-
nomics in their evaluations. Further research is warranted to
determine if there is a correlation between pharmacoeconomic
messaging and product uptake, with prescription or unit sales
analysis combined with large scale physician surveys on inﬂu-
ences of prescribing patterns.
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OBJECTIVE: The purpose of this study was to examine various
patient and provider characteristics associated with being pre-
scribed an aromatase inhibitors (AI) v. tamoxifen only therapy
among a cohort of North Carolina (NC) Medicaid enrollees
diagnosed with breast cancer. METHODS: Data was gathered
using the Linked NC Central Cancer Registry-Medicaid Claims
database which links NC cancer registry claims with Medicaid
data. A logistic regression model was built to determine the odds
of an individual ever receiving an AI during the study period.
RESULTS: A total of 600 patients were included, of which 451
(75.2%) and 149 (24.8%) received tamoxifen only and AI (alone
or in combination) therapy, respectively. Results showed that
patients who lived in urban areas (compared to rural), were
postmenopausal (based on age 55), had regional- or distant-
staged cancer (opposed to local or unknown), had been hospi-
talized in the year prior to treatment index, and had breast
conserving surgery (BCS) (rather than mastectomy) had 1.97
[1.29, 3.00], 2.26 [1.80, 2.83], 2.74 [1.79, 4.20], 1.87 [1.20,
2.92], 0.64 [0.41, 1.00] times the odds, respectively, of ever
receiving an AI compared to tamoxifen only. Additionally, for
every one-year increase in the time a patient started hormonal
therapy, the odds of receiving AI therapy (compared to tamoxifen
only) increased 2.26 [1.80, 2.83] fold. CONCLUSION: The
differences in antiestrogenic treatment type based on whether the
patient visited a hospital in the year prior to the study and in
whether the patient lived in urban or rural area may represent
disparities in access to advances in care. Furthermore, it may be
the case that women who undergo mastectomy or who have
locally staged cancer are not being treated aggressively enough
with novel antiestrogenic therapies.
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OBJECTIVE: To assess current utilization patterns and costs for
epoetin alfa (EPO) and darbepoetin alfa (DARB), two ESAs,
in managed care cancer patients receiving chemotherapy.
METHODS: Medical claims from the Ingenix Impact National
Managed Care Database between January 2006 and June 2007
were analyzed. Patients included were 18 years old, had 1
claim for cancer within 90 days prior to treatment initiation,
were newly initiated on EPO or DARB with 2 doses of either
drug, and received chemotherapy during ESA treatment. Mean
cumulative ESA dose was used to calculate ESA cost (based on
October 2007 wholesale acquisition cost [WAC]) and dose ratio.
RESULTS: A total of 2322 EPO and 4353 DARB formed the
study population. EPO patients were older (57.7 vs. 55.7 years;
p < 0.0001) and a lower proportion were women (65% vs. 69%;
p = 0.0002), compared to DARB patients. Mean ESA treatment
duration was slightly longer in the EPO group (59 vs. 55 days;
p = 0.0001). The mean cumulative dose (SD) was 312,723
(255,432) Units for EPO and 1174 (833) mcg for DARB, result-
ing in a dose ratio of 266:1 (Units EPO : mcg DARB). Based on
these doses, WAC-based ESA cost was 28% less for EPO than
for DARB (EPO $3915; DARB $5434; p < 0.0001). A sensitivity
analysis using January 2008 average sales price +6% also indi-
cated lower cost for EPO (EPO $2803; DARB $3396;
p < .0001). This ﬁnding was also maintained after adjusting for
age, gender, treatment duration, payer type, type of malignan-
cies, cancer treatments, and severity indicators, (adjusted cost
difference: $1788, p < 0.0001). CONCLUSION: This observa-
tional study of 6675 cancer patients reported a dose ratio of
266:1 which resulted in a 28% lower drug cost in the EPO
group compared to the DARB group. These ﬁndings provide
greater understanding of current real-world ESA utilization in
the managed care setting.
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OBJECTIVE: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. The aim of
this study is to analyze the three year screening rate (coverage)
of the organized cervical cancer screening programme in
women aged less than 25 years. Although women under 25
years are out of the scope of the organized screening pro-
gramme, but opportunistic screening may be applied.
METHODS: The data derive from the ﬁnancial database of
the National Health Insurance Fund Administration (OEP) of
Hungary covering the period of 2000–2002 (without organized
screening) and 2003–2005 (with organized screening). We cal-
culated the three-year screening rate for 2003–2005 according
to the age-group of women less than 25 years (15–19 and
20–24). Screening is deﬁned with cytological examination of
Papanicolau smear and includes all smears taken either within
or outside of the organized programme. RESULTS: The three-
year screening rate of women aged 25–64 years was 52.65 %
in 2003–2005. The coverage of women under 25 years was the
following in 2003–2005: 15–19 years: 31.94 %; 20–24 years:
61.20 %. Comparing this values to the coverage of 2000–2002
(without organized screening) we found a decreasing tendency
in these two age-groups: 15–19 years: -0.06 percent point
decrease (non-signiﬁcant), 20–24 years: -6.28 percent point
decrease (p < 0.01). CONCLUSION: We found that coverage
of women aged 20–24 being out of the scope of the organized
cervical cancer screening programme is higher (61.2 %) than
the average of target age group of 25–64 years (52.65). Despite
of this ﬁnding, the coverage of women 15–19 and 20–24
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showed a decreasing tendency following the introduction of
organized screening programme.
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OBJECTIVE: The cost of illness due to cancer is substantial in
terms of both human suffering and economic resources. The
growth in cancer treatment spending in the United States is due in
large part to increases in survival and cancer prevalence. The
objective of this study is to analyze the growth in spending on
direct medical costs for cancer treatment using a prevalence-based
cost-of-illness approach. Direct costs include personal health care
expenditures for hospital and nursing home care, physician and
other professional services, drugs, and home care. METHODS:
Estimates for cancer prevalence counts in the year 2004 were
derived by applying U.S. Census population data to National
Cancer Institute Surveillance Epidemiology and End Results
(SEER 9) and historical Connecticut Limited Duration Prevalence
proportions. Cancer treatment cost estimates were based on
Centers for Medicare & Medicaid Services projections for total
2005 health expenditures by type of direct costs, and the National
Center for Health Statistic’s methodology for calculating direct
costs for major diagnostic groups. Cancer treatment spending and
national health care expenditure values were adjusted to year
2005 dollars using the Consumer Price Index—All Urban Con-
sumers. RESULTS: From 1985 to 2004, inﬂation adjusted per-
capita national health care expenditures increased 70%, while
inﬂation adjusted cancer treatment spending per prevalent case
increased 16%. In 2004, cancer spending per prevalent case
($6862) was on par with per-capita total health care spending
($6492). CONCLUSION: Per-capita health care spending has
increased signiﬁcantly over the past two decades in comparison to
cancer spending per prevalent case. Prevalence-based costing
acknowledges that the direct costs of cancer care in any given year
are attributable to new and previously diagnosed cancer patients.
Our analysis underscores the importance of evaluating spending
on cancer care in the context of overall health care spending,
cancer survival rates, and disease prevalence.
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OBJECTIVE: Cancer continues to be a leading cause of death,
but the last few decades have seen many changes in the diagnosis
and treatment of the disease. In this study, we estimate the
economic value of gains in cancer survival over the last 20 years,
separate these gains into the portions due to improvements in
treatment and detection, and determine the extent to which the
economic value of gains in cancer survival have been divided
between patients and ﬁrms. METHODS: Using methodology
developed by Philipson and Jena (2005), we estimated the eco-
nomic value of gains in cancer survival between 1990 and 2000.
We then used estimates from the literature to calculate expendi-
tures on cancer treatment, thereby allowing us to determine how
the social value of gains in cancer treatment has been divided
between patients and ﬁrms. RESULTS: The value of survival
gains for all cancers combined was worth roughly $28,000–
$30,000 per cancer patient, and most (78–88%) of this gain has
been driven by improvements in treatment. For all cancers com-
bined, improvements in cancer survival between 1990 and 2000
had a social value of roughly $1.6–$1.9 trillion, and health care
providers were able to appropriate 6–19% of this total, with the
rest accruing to patients. CONCLUSION: The social value of
recent gains in cancer survival is very large. Most of this gain has
been driven by improvements in cancer treatment, and has been
appropriated by patients, not health care providers.
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OBJECTIVE: To describe how decision making in the Cancer
Subcommittee of the Ontario Committee to Evaluate Drugs
(responsible for deciding which novel and costly cancer drugs
will be funded in Ontario) is evolving along three scientiﬁc para-
digms. METHODS: We describe how these paradigms shape
both criteria and process of decision making. We also systemati-
cally reviewed meeting transcripts to analyze decisions made in
2006. RESULTS: Evidence Based Medicine (I) is part of decision
making through rigorous evidence reviews and the implicit rule
that drugs must pass the threshold of effectiveness to be funded.
Although drugs must pass one evidence threshold to be licenced
in Canada, higher standards are required for reimbursement (e.g.
phase III controlled trial data, peer reviewed publication). Health
economic criteria (II) are assuming greater weight in decision
making, as the review process is standardized, committee
members become more economically literate, and a cancer phar-
macoeconomics unit is established. The process of decision
making (versus decision criteria) is evolving using the ethical
foundations of Accountability for Reasonableness (III), impor-
tant tenets of which are transparency, accountability, and stake-
holder involvement in the decision process. Review of the 2006
decisions showed that 16 of 37 drugs were funded (43%).
Among negative funding decisions 86% were characterized by
inadequate evidence (main reason in 43%), 71% were charac-
terized by cost effectiveness concerns (main reason in 15% ), and
5% by ethical concerns (main reason in 5%). Forty-eight percent
of decisions were multifactorial. CONCLUSION: Each para-
digm used to make cancer drug funding decisions comes from a
distinct intellectual tradition. Most decisions in 2006 were based
on more than one paradigm. We believe that optimal decision
making for cancer drugs involves integrating concepts from all
traditions, involving both distinct decision criteria and decision
processes. Integration requires judicious tradeoffs between both
efﬁciency and equity, and evidence quality and efﬁciency/equity.
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OBJECTIVE: Evaluate predictors of four major therapeutic
choices (surgery, radiation, chemotherapy, immunotherapy) in
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